Cue Biopharma Statistics
Total Valuation
Cue Biopharma has a market cap or net worth of $149.07 million. The enterprise value is $134.73 million.
| Market Cap | 149.07M |
| Enterprise Value | 134.73M |
Important Dates
The next estimated earnings date is Wednesday, November 11, 2026, after market close.
| Earnings Date | Nov 11, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Cue Biopharma has 7.26 million shares outstanding. The number of shares has increased by 84.06% in one year.
| Current Share Class | 7.26M |
| Shares Outstanding | 7.26M |
| Shares Change (YoY) | +84.06% |
| Shares Change (QoQ) | +31.90% |
| Owned by Insiders (%) | 7.34% |
| Owned by Institutions (%) | 22.71% |
| Float | 6.36M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 4.14 |
| Forward PS | 76.63 |
| PB Ratio | 48.56 |
| P/TBV Ratio | 67.46 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 3.76 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.25, with a Debt / Equity ratio of 1.33.
| Current Ratio | 1.25 |
| Quick Ratio | 1.07 |
| Debt / Equity | 1.33 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -508.47 |
Financial Efficiency
Return on equity (ROE) is -1,603.48% and return on invested capital (ROIC) is -395.46%.
| Return on Equity (ROE) | -1,603.48% |
| Return on Assets (ROA) | -172.66% |
| Return on Invested Capital (ROIC) | -395.46% |
| Return on Capital Employed (ROCE) | -1,039.56% |
| Weighted Average Cost of Capital (WACC) | 18.44% |
| Revenue Per Employee | $1.30M |
| Profits Per Employee | -$5.66M |
| Employee Count | 29 |
| Asset Turnover | 1.05 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Cue Biopharma has paid $500,000 in taxes.
| Income Tax | 500,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +3.62% in the last 52 weeks. The beta is 2.63, so Cue Biopharma's price volatility has been higher than the market average.
| Beta (5Y) | 2.63 |
| 52-Week Price Change | +3.62% |
| 50-Day Moving Average | 25.54 |
| 200-Day Moving Average | 21.15 |
| Relative Strength Index (RSI) | 48.21 |
| Average Volume (20 Days) | 162,330 |
Short Selling Information
The latest short interest is 792,553, so 10.91% of the outstanding shares have been sold short.
| Short Interest | 792,553 |
| Short Previous Month | 702,198 |
| Short % of Shares Out | 10.91% |
| Short % of Float | 12.46% |
| Short Ratio (days to cover) | 1.70 |
Income Statement
In the last 12 months, Cue Biopharma had revenue of $37.66 million and -$164.11 million in losses. Loss per share was -$36.22.
| Revenue | 37.66M |
| Gross Profit | -37.34M |
| Operating Income | -98.64M |
| Pretax Income | -163.61M |
| Net Income | -164.11M |
| EBITDA | -97.28M |
| EBIT | -98.64M |
| Loss Per Share | -$36.22 |
Balance Sheet
The company has $17.41 million in cash and $3.08 million in debt, with a net cash position of $14.34 million or $1.97 per share.
| Cash & Cash Equivalents | 17.41M |
| Total Debt | 3.08M |
| Net Cash | 14.34M |
| Net Cash Per Share | $1.97 |
| Equity (Book Value) | 2.31M |
| Book Value Per Share | 0.44 |
| Working Capital | 5.41M |
Cash Flow
In the last 12 months, operating cash flow was -$50.05 million and capital expenditures -$121,000, giving a free cash flow of -$50.17 million.
| Operating Cash Flow | -50.05M |
| Capital Expenditures | -121,000 |
| Depreciation & Amortization | 1.36M |
| Net Borrowing | -2.50M |
| Free Cash Flow | -50.17M |
| FCF Per Share | -$6.91 |
Margins
| Gross Margin | -99.15% |
| Operating Margin | -261.97% |
| Pretax Margin | -434.49% |
| Profit Margin | n/a |
| EBITDA Margin | -258.36% |
| EBIT Margin | -261.97% |
| FCF Margin | n/a |
Dividends & Yields
Cue Biopharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -84.06% |
| Shareholder Yield | -84.06% |
| Earnings Yield | -176.52% |
| FCF Yield | -32.20% |
Analyst Forecast
The average price target for Cue Biopharma is $88.00, which is 328.85% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $88.00 |
| Price Target Difference | 328.85% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (3Y) | -30.10% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on April 24, 2026. It was a reverse split with a ratio of 1:30.
| Last Split Date | Apr 24, 2026 |
| Split Type | Reverse |
| Split Ratio | 1:30 |
Scores
Cue Biopharma has an Altman Z-Score of -32 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -32 |
| Piotroski F-Score | 3 |